< Back to previous page
Researcher
Eric Van Cutsem
- Disciplines:Oncology
Affiliations
- Digestive Oncology (Division)
Member
From1 Aug 2022 → Today - Clinical Digestive Oncology (Division)
Member
From1 Jan 2012 → 31 Jul 2022 - Translational Research in GastroIntestinal Disorders (Division)
Member
From1 Oct 1999 → 31 Dec 2011
Projects
1 - 10 of 12
- SAFIR-ABC10: molecular screening for precision medicine in advanced biliary cancersFrom1 Jan 2022 → TodayFunding: Foundations, funds and other with scientific goal
- The search for biomarkers in systemic treatment of advanced hepatocellular carcinoma.From1 Oct 2019 → TodayFunding: FWO Strategic Basic Research Grant
- Identification of candidate biomarkers of intrinsic and acquired resistance to anti-angiogenic agents in metastatic colorectal cancer.From1 Jan 2013 → 31 Dec 2014Funding: Private funding of national origin - undefined
- Genetic biomarkers for anti-angiogenic therapies - a translational approach.From1 Jan 2011 → 31 Dec 2013Funding: Private funding of national origin - undefined
- The role of the forkhead transcription factor FOXP1 in cancer.From1 Jan 2011 → 31 Dec 2014Funding: FWO research project
- Technical research platform & heavy equipment HiSeq200 (including CBOT computing system and warranty).From1 Sep 2010 → 31 Aug 2013Funding: Other federal scientific institutions
- Imaging for early response prediction to EGF-receptor blocking monoclonal antibodies in combination therapy for colorectal cancer.From1 Jan 2009 → 31 Dec 2012Funding: IWT - TBM (Applied Biomedical Research)
- Can response to epidermal growth factor receptor antibodies in metastatic colorectal cancer be predicted? Advanced bio-informatics tools integrating gene mutation and microarray data may hold the key.From1 Jan 2009 → 31 Dec 2012Funding: Private funding of national origin - undefined
- Can response to Epidermal Growth Factor Receptor antibodies in patients with metastatic Colorectal Cancer be predicted? Advanced bio-informatics tools, integrating gene mutation, microarray and proteomics data may hold the key.From1 Jan 2009 → 31 Dec 2012Funding: FWO research project
- A phase I dose-escalation study to determine the maximum tolerated dose of radiotherapy, in combination with concomitant 5-FU chemptherapy, in patients with locally advanced rectal cancer with a positive circumferential resection margin (cCRM).From1 Jan 2009 → 31 Dec 2010Funding: Private funding of national origin - undefined
Publications
1 - 10 of 714
- The ongoing search for biomarkers of response to systemic therapy in advanced hepatocellular carcinoma.(2023)
Authors: Sarah Cappuyns, Jeroen Dekervel, Eric Van Cutsem, Chris Verslype, Diether Lambrechts
- Body weight loss as a prognostic and predictive factor in previously treated patients with metastatic gastric cancer: post hoc analyses of the randomized phase III TAGS trial(2023)
Authors: Eric Van Cutsem
- Pembrolizumab for previously treated, microsatellite instability-high/mismatch repair-deficient advanced colorectal cancer: final analysis of KEYNOTE-164.(2023)
Authors: Eric Van Cutsem
Pages: 185 - 195 - 18F-Labeled Somatostatin Analogs as PET Tracers for the Somatostatin Receptor: Ready for Clinical Use(2023)
Authors: Hannes Leupe, Stephen Ahenkorah, Jeroen Dekervel, Eric Van Cutsem, Chris Verslype, Frederik Cleeren, Christophe Deroose
Pages: 835 - 841 - Zolbetuximab plus mFOLFOX6 in patients with CLDN18.2-positive, HER2-negative, untreated, locally advanced unresectable or metastatic gastric or gastro-oesophageal junction adenocarcinoma (SPOTLIGHT): a multicentre, randomised, double-blind, phase 3 trial.(2023)
Authors: Eric Van Cutsem
Pages: 1655 - 1668 - ANCHOR CRC: Results From a Single-Arm , Phase II Study of Encorafenib Plus Binimetinib and Cetuximab in Previously Untreated BRAF(V600E)-Mutant Metastatic Colorectal Cancer(2023)
Authors: Eric Van Cutsem, Jeroen Dekervel
Pages: 2628 - + - Trifluridine-Tipiracil and Bevacizumab in Refractory Metastatic Colorectal Cancer(2023)
Authors: Eric Van Cutsem
Pages: 1657 - 1667 - Tucatinib plus trastuzumab for chemotherapy-refractory, HER2-positive, RAS wild-type unresectable or metastatic colorectal cancer (MOUNTAINEER): a multicentre, open-label, phase 2 study.(2023)
Authors: Eric Van Cutsem
Pages: 496 - 508 - Tislelizumab plus chemotherapy versus placebo plus chemotherapy as first-line treatment for advanced or metastatic oesophageal squamous cell carcinoma (RATIONALE-306): a global, randomised, placebo-controlled, phase 3 study(2023)
Authors: Eric Van Cutsem
Pages: 483 - 495 - Adjuvant nab-Paclitaxel plus Gemcitabine in Resected Pancreatic Ductal Adenocarcinoma: Results From a Randomized, Open -Label, Phase III Trial(2023)
Authors: Eric Van Cutsem
Pages: 2007 - +